Pathophysiology and treatment of diabetic retinopathy (Q34528134)

2 August 2017

1 reference

title

Pathophysiology and treatment of diabetic retinopathy (English)

1 reference

2 August 2017

1 reference

1

Francesco Bandello

1 reference

2 August 2017

Rosangela Lattanzio

2

1 reference

2 August 2017

Ilaria Zucchiatti

series ordinal

3

1 reference

2 August 2017

Claudia Del Turco

series ordinal

4

1 reference

2 August 2017

publication date

1 January 2013

1 reference

2 August 2017

1 reference

2 August 2017

volume

50

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

1-20

1 reference

Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Diabetic macular edema: pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Clinical review: The role of advanced glycation end products in progression and complications of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Retinal heat shock protein 25 in early experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

AGEs, RAGE, and diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Aldose reductase in diabetic microvascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Activation of protein kinase C isoforms and its impact on diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Homocysteine levels in the vitreous of proliferative diabetic retinopathy and rhegmatogenous retinal detachment: its modulating role on lysyl oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Immunological mechanisms in the pathogenesis of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Angiotensin-(1-7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Local multifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Multifocal electroretinogram and short-wavelength automated perimetry measures in diabetic eyes with little or no retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

The potential role of glutamate in the current diabetes epidemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Diabetes downregulates presynaptic proteins and reduces basal synapsin I phosphorylation in rat retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Effect of obesity and glycemic control on serum lipocalins and insulin-like growth factor axis in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Management of newly diagnosed patients with type 2 diabetes: what are the attitudes of physicians? A SUBITO!AMD survey on the early diabetes treatment in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Post-prandial glucose and diabetic complications: systematic review of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Insulin resistance is associated with elevated serum pigment epithelium-derived factor (PEDF) levels in morbidly obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Lipid accumulation in overweight type 2 diabetic subjects: relationships with insulin sensitivity and adipokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Diabetic macular edema. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Prevalence of diabetic retinopathy in the United States, 2005-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Blindness in a 25-year follow-up of a population-based cohort of Danish type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Burden of illness of diabetic macular edema: literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Steroids as part of combination treatment: the future for the management of macular edema?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Progressive Enlargement of Laser Scars Following Grid Laser Photocoagulation for Diffuse Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Short-duration focal pattern grid macular photocoagulation for diabetic macular edema: four-month outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

"Light" versus "classic" laser treatment for clinically significant diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Micropulse and continuous wave diode retinal photocoagulation: visible and subvisible lesion parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Functional outcome of subthreshold versus threshold diode laser photocoagulation in diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Randomized Clinical Trial Evaluating mETDRS versus Normal or High-Density Micropulse Photocoagulation for Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Selective retinal therapy with microsecond exposures using a continuous line scanning laser

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Semiautomated patterned scanning laser for retinal photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Healing of retinal photocoagulation lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Pain responses of Pascal 20 ms multi-spot and 100 ms single-spot panretinal photocoagulation: Manchester Pascal Study, MAPASS report 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Experience with the Pascal® photocoagulator: an analysis of over 1,200 laser procedures with regard to parameter refinement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Spectral-domain optical coherence tomography imaging of retinal changes after conventional multicolor laser, subthreshold micropulse diode laser, or pattern scanning laser therapy in Japanese with macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Clinical Evaluation and Treatment Accuracy in Diabetic Macular Edema Using Navigated Laser Photocoagulator NAVILAS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Pain and accuracy of focal laser treatment for diabetic macular edema using a retinal navigated laser (Navilas).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Time required for navigated macular laser photocoagulation treatment with the Navilas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Effect of pulse duration on size and character of the lesion in retinal photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Fundus autofluorescence and Fourier-domain optical coherence tomography imaging of 10 and 20 millisecond Pascal retinal photocoagulation treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Recent advances in drug delivery systems for treating ocular complications of systemic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal steroids for macular edema: the past, the present, and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Role of steroids in the treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Association of vitreous inflammatory factors with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

A Phase 2/3, Multicenter, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Subconjunctival sirolimus in the treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Ocular oxygenation and the treatment of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Optical cross-sectional observation of resolved diabetic macular edema associated with vitreomacular separation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Surgery for diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Vitrectomy for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Inhibitors of ocular neovascularization: promises and potential problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Combined rhegmatogenous and traction retinal detachment in proliferative diabetic retinopathy: clinical manifestations and surgical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Corneal epithelial defects following vitrectomy surgery using hand-held, sew-on, and noncontact viewing lenses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Surgical management of the late complications of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Intravitreal triamcinolone reduces the morphologic changes of ciliary body after pars plana vitrectomy for retinal vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Combination of vitrectomy, IVTA, and laser photocoagulation for diabetic macular edema unresponsive to prior treatments; 3-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

21 January 2018

Enzymatic vitreolysis.

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

INTRAVITREAL BEVACIZUMAB AND PANRETINAL PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY ASSOCIATED WITH VITREOUS HEMORRHAGE

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00592-012-0449-3

10.1007/S00592-012-0449-3

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1008215122

0 references

1 reference